Last reviewed: June 28, 2026

Last updated: June 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Mounjaro (tirzepatide) and Wegovy (semaglutide) are both FDA-approved medications for chronic weight management, but they work through different biological pathways. Tirzepatide activates two hormone receptors—GLP-1 and GIP—while semaglutide targets GLP-1 alone, leading to distinct efficacy profiles and side effect patterns that vary by person.

How Tirzepatide and Semaglutide Differ at the Cellular Level

Tirzepatide, the active compound in Mounjaro, binds to both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual mechanism increases insulin secretion, reduces appetite through brain signaling, and slows stomach emptying more robustly than single-pathway agents. Semaglutide in Wegovy activates only the GLP-1 receptor, which still reduces hunger and regulates blood sugar but through a narrower biological window.

The GIP pathway—unique to tirzepatide—plays a role in energy expenditure and fat tissue function. Some patients experience greater weight loss with the added GIP activation, while others tolerate the single GLP-1 pathway better because it produces fewer or milder gastrointestinal effects. Your genetic predisposition for GIP receptor sensitivity (GIPR rs1800437 variant) influences how much benefit you may gain from tirzepatide's dual action.

Clinical Weight Loss Results: Tirzepatide vs Semaglutide Trials

The STEP trials for semaglutide showed average weight loss of 15-22% of baseline body weight over 68 weeks at the highest dose. The SURMOUNT trials for tirzepatide demonstrated average reductions of 20-22.5% at comparable timepoints, with some patients losing up to 25% of their starting weight. These ranges overlap, but individual response varies significantly based on metabolism, adherence, diet, and genetic factors rather than medication choice alone.

Head-to-head comparisons are limited, so claims of clear superiority for either drug should be approached cautiously. Real-world outcomes depend heavily on dose escalation tolerance, lifestyle integration, and baseline metabolic health. PlexusDx helps identify which compound and formulation may align better with your genetic profile through the Precision Peptide Genetic Test, which maps 14 metabolic pathways and 49 peptide-related variants.

Side Effects and Tolerability: What Sets Them Apart

Both medications carry similar gastrointestinal side effects—nausea, vomiting, constipation, and diarrhea—especially during dose escalation. Tirzepatide's dual pathway may produce more pronounced early nausea in some users, though this often resolves within 4-8 weeks. Semaglutide typically has a slightly gentler initiation phase for tolerability-sensitive patients, making it preferred for those with a history of medication sensitivities.

Pancreatitis, thyroid concerns, and gallbladder issues are rare but possible with both agents and require medical monitoring. Tirzepatide has been associated with cases of retinopathy (eye complications) in diabetic patients, though causality remains under investigation. If you have a personal or family history of thyroid cancer or multiple endocrine neoplasia, discuss contraindications with your PlexusDx provider before starting either compound.

Choosing Between Tirzepatide and Semaglutide: What Matters Most

Your choice should hinge on baseline health status, prior medication experiences, genetic markers, and treatment goals rather than brand name alone. Patients with insulin resistance or prediabetes may benefit more from tirzepatide's dual GLP-1/GIP action, while those seeking maximum tolerability on first attempt might start with semaglutide. PlexusDx offers both compounds as injections and oral formulations, giving you flexibility to switch if needed without changing prescriber.

Cost and access play practical roles: PlexusDx Compounded Tirzepatide Injection starts at $249/month, while Compounded Semaglutide Injection begins at $149/month. Both are HSA/FSA eligible, require no insurance, and come from licensed 503A compounding pharmacies across all 50 states. Your dose may need to go up. Your price won't. Adding the Precision Peptide Genetic Test ($99 after your first month) reveals your genetic predispositions for GLP1R (rs6923761), GIPR (rs1800437), and FTO (rs9939609) variants, helping optimize your compound and protocol selection.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Which medication causes more weight loss: Mounjaro or Wegovy?

Clinical trials show tirzepatide (Mounjaro) and semaglutide (Wegovy) produce overlapping weight loss ranges of 15-25%, with tirzepatide trending slightly higher on average. Individual results depend far more on genetics, adherence, lifestyle, and dose tolerance than on medication type alone. PlexusDx helps predict your personal response through genetic testing.

Does tirzepatide's GIP receptor activation really make a difference?

Yes. The GIP pathway boosts insulin secretion and energy expenditure beyond GLP-1 alone, which is why some patients lose more weight with tirzepatide. However, not everyone's GIP receptor is equally responsive—your GIPR rs1800437 genetic variant influences this. The Precision Peptide Genetic Test reveals your GIP sensitivity to guide therapy selection.

Can I switch from Wegovy to Mounjaro if I'm not seeing results?

Yes, switching between compounded semaglutide and tirzepatide is possible and often done in clinical practice. PlexusDx can facilitate this transition with proper dose escalation guidance. Many patients who plateau on one compound find renewed progress with the other, thanks to their different mechanisms.

Which has fewer side effects: semaglutide or tirzepatide?

Semaglutide often has a gentler initial tolerability profile, while tirzepatide may cause stronger early nausea due to its dual action. Long-term side effect rates are similar. Tolerability is highly individual and influenced by genetics, baseline metabolism, and dose escalation speed rather than the medication itself.

Does the Precision Peptide Genetic Test predict which medication will work better for me?

The test maps 150+ genetic insights across 14 metabolic pathways, including GLP1R, GIPR, FTO, and MC4R variants that influence appetite regulation and medication response. While it doesn't guarantee outcomes, it provides evidence-based guidance on whether you're a better fit for GLP-1 monotherapy (semaglutide) or dual GLP-1/GIP therapy (tirzepatide). PlexusDx adds this test for $99 after your first month of treatment.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves